US2017027991A1PendingUtilityA1

Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases

39
Assignee: BONE THERAPEUTICSPriority: Feb 15, 2008Filed: Aug 15, 2016Published: Feb 2, 2017
Est. expiryFeb 15, 2028(~1.5 yrs left)· nominal 20-yr term from priority
Inventors:Enrico Bastianelli
A61P 29/00A61P 19/02A61P 21/00A61P 19/00A61P 19/08A61P 19/06A61K 31/728A61K 47/36A61K 35/32A61K 31/4168A61K 35/28A61K 2035/124A61K 9/0019Y02A50/30
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition for the acute and/or chronic treatment or prevention of osteoarticular diseases includes an adequate pharmaceutical carrier or diluent, a polysaccharide and/or a glycosaminoglycan, an anti-inflammatory agent and stem cells.

Claims

exact text as granted — not AI-modified
1 .- 14 . (canceled) 
     
     
         15 . A method of treating a osteoarticular disease in a mammalian subject, comprising administering to the subject a pharmaceutical composition comprising:
 one or more glycosaminoglycan(s)   an effective amount of mesenchymal stem cells   an effective amount of an anti-inflammatory compound selected from the group consisting of an alpha 2 adrenergic receptor agonist, a corticosteroid, a non-steroidal anti-inflammatory drug, an anti-TNF-alpha antibody; and   
       wherein the pharmaceutical composition reduces joint degeneration in the subject associated with the osteoarticular disease thereby providing clinical improvement of the osteoarticular disease. 
     
     
         16 . The method according to  claim 15 , wherein an injectable solution is administrated to the subject. 
     
     
         17 . The method according to  claim 15 , wherein the pharmaceutical composition is administered to the subject through intra-articular injection. 
     
     
         18 . The method according to  claim 16 , wherein the injectable solution is administered to the subject twice a week. 
     
     
         19 . The method according to  claim 16 , wherein the injectable solution is administered to the subject once a week. 
     
     
         20 . The method according to  claim 16 , wherein the injectable solution is administered to the subject once in two or three weeks or less. 
     
     
         21 . The method according to  claim 15 , which comprises administering an amount of the pharmaceutical composition such that the subject receives from about 0.1 to about 100 mg/kg of body weight of anti-inflammatory compound. 
     
     
         22 . The method according to  claim 15 , which comprises administering an amount of the pharmaceutical composition such that the subject receives from about 0.1 to about 100 mg/kg of body weight of the glycosaminoglycan. 
     
     
         23 . The method according to  claim 15 , wherein the mesenchymal stem cells are obtained from bone marrow concentrate. 
     
     
         24 . The method according to  claim 15 , wherein the osteoarticular disease is osteoarthritis, degenerative arthritis, gonarthrosis, coxarthrosis, gout, chondrocalcinosis, calcium hydroxyapatite crystal deposition disease, spondyloarthropathies, ankylosing spondylitis, Reiter's Syndrome, psoriatic arthropathy, enteropathic arthritis, rheumatoid arthritis, neuropathic arthropathy, or acute rheumatic fever. 
     
     
         25 . The method of  claim 15 , wherein the subject is a human. 
     
     
         26 . The method of  claim 15 , wherein the pharmaceutical composition further comprises a pharmaceutical adequate carrier or diluent.

Join the waitlist — get patent alerts

Track US2017027991A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.